Cancer drugs often fail not because they are weak, but because they never reach the exact place they are supposed to act, all the way down to the tiny structures inside tumour cells. Researchers at the National University of Singapore have developed a new way to search for nanoparticles that can carry treatment directly to […]
The updated Phase 1/2 data for concurrent enzalutamide plus cabazitaxel in chemo‑naïve mCRPC show deep biochemical responses and a promising signal for progression‑free outcomes, but the dataset remains hypothesis‑generating. In a multi‑institutional single‑arm trial of enzalutamide with cabazitaxel (plus prednisone), 35 patients were included in the efficacy analysis with a median follow‑up of 23.7 months; […]
Orlistat is a well‑known weight‑loss drug that also blocks a key enzyme cancer cells use to make fats, and researchers have been trying to re‑use it against tumors for years. Recently a team developed a new way to deliver orlistat directly into prostate cancer cells by packing it inside tiny, engineered particles called Cys8E nanoparticles […]
A new, promising concept was explored for men with metastatic castration‑resistant prostate cancer: PSMA‑targeted CAR‑NK cells engineered to be an off‑the‑shelf immunotherapy that aims to combine targeted tumor killing with a safer toxicity profile. The work, presented at AUA 2026 meeting, comes from investigators affiliated with the Cancer Hospital, Chinese Academy of Medical Sciences, who […]
177Lu-D-Dan-Phe-PSMA, also called 177Lu-LNC1011, represents a next-generation PSMA-targeted radioligand therapy designed to improve on existing options like Pluvicto for metastatic castration-resistant prostate cancer (mCRPC). Unlike Pluvicto, which clears rapidly through the kidneys and limits sustained tumor exposure, this agent incorporates a dansyl modification for prolonged intratumoral retention while preserving systemic clearance. Early phase 1 results […]
Researchers at Roswell Park Comprehensive Cancer Center have identified a critical vulnerability in how prostate cancers escape standard hormonal therapy. The study reveals that when androgen receptor signaling is suppressed by ADT or AR pathway inhibitors, cancer cells compensate by ramping up BCL-2, an anti-apoptotic protein that helps them survive treatment. The findings suggest that […]
OncoACP3‑DOTA is a small‑molecule ligand directed at prostatic acid phosphatase (ACP3, also historically called PAP), a membrane‑bound phosphatase that is highly specific to the prostate, with only weak expression in normal tissues such as kidney. Preclinical work showed that ACP3 is retained in many prostate tumors, including lesions with low or absent PSMA expression, and […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! This week’s newsletter is a bit lighter than usual, partly because it’s becoming increasingly difficult to find detailed information on new clinical trials. The trials are there, but the mechanisms behind the proposed drugs are often hard to identify. […]
A new CRISPR system recently published in Nature could change how we think about selectively eliminating cancer cells without touching healthy tissue. Instead of using the classic Cas9 to edit DNA, researchers have repurposed Cas12a2, an enzyme that first binds to a specific RNA sequence and then unleashes a wave of DNA destruction across the […]
Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses. A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the […]